SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (147)2/24/1999 12:11:00 AM
From: Pseudo Biologist  Read Replies (1) of 416
 
Rick, the real reason is that scientists like to be in the cutting edge. CD2, the antigen of 507, is (supposed to be) old hat. While CD40 and even more, CD40L (what is it? CD154??), do sound more like "cutting edge" to me.

More seriously, yes, the literature seems more definite on the role of CD40 on antibody blocking and, in general, blocking that "second signal" (and the CD28/CTLA4/B7 etc for that matter), than on CD2. It also seems to this non-immunologist that several anti-CD40L antibodies have good properties, while not all ant-CD2 ones are created equal, with 507 appearing particularly special.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext